Just read how in the UK, drugs like Aricpet, Exelon, and Reminyl are no longer available as treatment for mild cases of Alzheimer’s disease.
They are felt to offer too little benefit compared to their expense.
I believe this offers a taste of things to come in the US, as healthcare funds become more and more scarce.
Share This Post:![[Slashdot]](http://www.smart-kit.com/wp-content/uploads/_graphics/slashdot-big.png)
![[Reddit]](http://www.smart-kit.com/wp-content/uploads/_graphics/reddit-big.png)
![[Facebook]](http://www.smart-kit.com/wp-content/uploads/_graphics/facebook-icon.gif){kind=icon}
![[Google]](http://www.smart-kit.com/wp-content/uploads/_graphics/google-bookmark-big.png)
![[StumbleUpon]](http://www.smart-kit.com/wp-content/uploads/_graphics/stumble-big.png)
![[Digg]](http://www.smart-kit.com/wp-content/uploads/_graphics/digg-big.png)
Came across a study published in the September 2006 issue of the European Journal of Neurology that compares Ginkgo Biloba to Aricept in the treatment of mild to moderate Alzheimer’s disease.
Aricept is a cholinesterase inhibitor- it boosts the amount of acetylcholine available in the brain for nerve cell communication. Reminyl and Exelon are also used to treat Alzheimer’s disease, and work in a similar fashion
There aren’t many studies that compare the two head to head, but this one shows Ginkgo Biloba is clinically as effective as Aricept.
Share This Post:
Subscribe
